Efficacy and Safety of Hepatitis B Virus Vaccine(HBV) in Treatment of Cutaneous Warts

• Status: Not yet recruiting
• Trial end date: 2024-08-20
• Target enrollment: 0
• Participant gender: All

Summary

Aim of the work:

1. Evaluate efficacy and safety of Intralesional HBV vaccine injection as a treatment of plane and genital warts.

2. Evaluate efficacy and safety of Intramuscular HBV vaccine injection as a treatment of plane and genital warts.

3. Compare the efficacy of different doses(0.3ml vs 0.5ml )of intralesional HBV vaccine injection for treatment of plane and genital warts.

4. Compare the efficacy of intralesional HBV vaccine injection vs Intramuscular HBV vaccine injection in treatment of plane and genital warts.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University

Criteria

Inclusion Criteria:

• Any patients with multiple genital or plane warts of any site.

• Patients age above 10 years old

• No concurrent systemic or topical treatment of warts

Exclusion Criteria:

• Pregnancy and lactation.

• History of any bleeding, clotting disorder or using anticoagulants

• Chronic systemic diseases such as chronic renal failure, hepatic insufficiency, and cardiovascular disorders.

• Concurrent use of systemic or topical treatments of warts.

• Patients with history of neuropathy or peripheral ischemia.

• Patients with signs of inflammation or infection.

• Patients with history of a serious systemic or anaphylactic reaction or allergy to a prior dose of HBV vaccine or to any of its components.